Skip to main content
letter
. 2020 Aug 10;2(4):168–172. doi: 10.2991/chi.k.200719.001

Table S2.

Univariate and multivariate analysis of risk factors for blood culture days

Variable Number of observations Univariate analysis p Multivariate analysis p
HR (95% CI) HR (95% CI)
Demographics
Age
  <50 14 Reference Reference
  50–60 36 0.94 (0.77; 1.15) 0.567 0.67 (0.53; 0.85) 0.001
  60–70 106 1.07 (0.90; 1.28) 0.434 0.67 (0.54; 0.83) <0.001
  >70 146 1.01 (0.84; 1.21) 0.939 0.61 (0.49; 0.75) <0.001
Sex
  Male 175 Reference Reference
  Female 127 0.85 (0.79; 0.93) <0.001 0.93 (0.85; 1.03) 0.154
CRAB features
  Hemoglobin <6.2 mmol/L 102 0.85 (0.82; 0.88) <0.001 0.91 (0.86; 0.95) <0.001
  Ionized calcium >1.345 mmol/L 79 1.65 (1.36; 2.01) <0.001 1.38 (1.09; 1.76) 0.008
  Creatinine >177 μmol/L 57 1.00 (1.00; 1.00) <0.001 1.00 (1.00; 1.00) 0.005
  Osteolytic lesion on either skeletal X-ray or WBLDCT not present 97 Reference Reference
  Osteolytic lesion on either skeletal X-ray or WBLDCT present 205 0.85 (0.78; 0.93) <0.001 0.75 (0.68; 0.83) <0.001
Immunoglobulins
  IgA ≥ 0.7 g/L (excluding patients with IgA M-protein isotype) 133 Reference Reference
  IgA < 0.7 g/L (excluding patients with IgA M-protein isotype) 169 1.05 (0.97; 1.14) 0.213 0.91 (0.80; 1.04) 0.180
  IgG ≥ 6.1 g/L (excluding patients with IgG M-protein isotype) 190 Reference Reference
  IgG < 6.1 g/L (excluding patients with IgG M-protein isotype) 112 1.33 (1.23; 1.45) <0.001 0.61 (0.49; 0.75) <0.001
  IgM ≥ 0.4 g/L 50 Reference Reference
  IgM < 0.4 g/L 252 1.90 (1.67; 2.17) <0.001 1.77 (1.48; 2.11) <0.001
M-protein isotype
  IgA 59 1.44 (1.30; 1.60) <0.001 1.52 (1.18; 1.94) 0.001
  IgG 168 Reference Reference
  Light-chain only 54 1.02 (0.91; 1.14) 0.789 1.37 (1.11; 1.69) 0.004
  Non-secretory 6 0.76 (0.55; 1.04) 0.088 1.06 (0.72; 1.56) 0.779
  Other 2 2.71 (1.68; 4.39) <0.001 4.15 (2.34; 7.34) <0.001
Myeloma risk profile
  ISS I 88 Reference Reference
  ISS II 92 1.11 (1.00; 1.23) 0.043 1.01 (0.89; 1.14) 0.848
  ISS III 72 1.55 (1.39; 1.73) <0.001 0.87 (0.75; 1.01) 0.076
  ISS not determined 47 1.16 (1.02; 1.32) 0.024 0.92 (0.79; 1.08) 0.300
  High risk cytogenetics [t(4;14), t(14;16) or del(17p)] by FISH not present 254 Reference Reference
  High risk cytogenetics [t(4;14), t(14;16) or del(17p)] by FISH present 48 1.18 (1.06; 1.32) 0.003 0.99 (0.87; 1.13) 0.875
ECOG Performance status
  0 111 Reference Reference
  1 116 1.41 (1.28; 1.54) <0.001 1.41 (1.27; 1.56) <0.001
  2 45 1.25 (1.09; 1.43) 0.001 1.12 (0.97; 1.30) 0.129
  3 26 1.47 (1.27; 1.69) <0.001 1.40 (1.17; 1.66) <0.001
Best response to ongoing line of therapy §
  sCR/CR/VGPR 1050 Reference Reference
  PR/MR 1136 1.23 (1.13; 1.35) <0.001 1.45 (1.29; 1.63) <0.001
  SD/PD 442 1.42 (1.26; 1.60) <0.001 1.46 (1.24; 1.71) <0.001
Number of prior lines of therapy §
  1 873 Reference Reference
  2 519 0.95 (0.85; 1.07) 0.415 1.15 (1.00; 1.33) 0.051
  3 400 1.10 (0.97; 1.26) 0.131 1.27 (1.07; 1.50) 0.006
  4 314 1.30 (1.13; 1.50) <0.001 1.42 (1.16; 1.74) 0.001
  5 191 0.94 (0.80; 1.12) 0.513 0.91 (0.72; 1.15) 0.429
  6 212 1.60 (1.35; 1.90) <0.001 1.83 (1.43; 2.33) <0.001
  7+ 276 1.05 (0.89; 1.23) 0.566 1.45 (1.14; 1.84) 0.002
Ongoing line of therapy by regimen §
  Melphalan 200 mg/m2 days 0–30 434 1.19 (1.04; 1.37) 0.012 1.28 (1.07; 1.53) 0.006
  IMID ± steroid 487 Reference Reference
  PI ± steroid 280 1.72 (1.46; 2.02) <0.001 1.80 (1.50; 2.15) <0.001
  CH ± steroid 201 2.01 (1.68; 2.40) <0.001 1.79 (1.48; 2.18) <0.001
  IMID + PI ± steroid 224 1.29 (1.08; 1.53) 0.004 1.19 (0.99; 1.44) 0.067
  PI + CH ± steroid 173 1.48 (1.23; 1.78) <0.001 0.94 (0.76; 1.16) 0.547
  IMID + CH ± steroid 301 1.46 (1.24; 1.70) <0.001 1.14 (0.95; 1.36) 0.165
  Daratumumab ± steroid 147 1.15 (0.93; 1.42) 0.192 1.29 (1.02; 1.63) 0.033
  Daratumumab + PI ± steroid 37 0.60 (0.41; 0.89) 0.011 0.90 (0.59; 1.37) 0.624
  Daratumumab + IMID ± steroid 171 1.26 (1.04; 1.53) 0.020 1.21 (0.97; 1.51) 0.094
  Daratumumab + PI + IMID ± steroid 3 0.79 (0.25; 2.45) 0.677 0.85 (0.26; 2.82) 0.791
  Five or more drugs 294 2.18 (1.87; 2.54) <0.001 1.79 (1.50; 2.14) <0.001
  Other 33 2.31 (1.50; 3.55) <0.001 1.02 (0.63; 1.63) 0.949
Time from diagnosis §
  0–91 days after 77 Reference Reference
  92–183 days after 472 0.53 (0.45; 0.63) <0.001 0.52 (0.42; 0.65) <0.001
  183–365 days after 278 0.61 (0.51; 0.72) <0.001 0.44 (0.34; 0.56) <0.001
  365–730 days after 270 0.40 (0.34; 0.47) <0.001 0.26 (0.20; 0.32) <0.001
  More than 730 days after 404 0.26 (0.23; 0.30) <0.001 0.12 (0.10; 0.16) <0.001
Time from initiation of immunoglobulin replacement therapy §
  Before 524 Reference Reference
  0–91 days after 335 2.34 (2.02; 2.71) <0.001 2.06 (1.75; 2.43) <0.001
  92–183 days after 179 1.57 (1.31; 1.88) <0.001 1.26 (1.02; 1.56) 0.033
  184–365 days after 249 2.39 (2.03; 2.82) <0.001 2.05 (1.69; 2.48) <0.001
Time from dates of progressive disease §
  Before 1315 Reference Reference
  0–91 days after 281 1.13 (0.98; 1.30) 0.087 1.17 (1.00; 1.37) 0.051
  92–183 days after 33 0.95 (0.65; 1.40) 0.810 0.91 (0.59; 1.41) 0.682
  184–365 days after 20 0.61 (0.37; 1.01) 0.054 0.71 (0.39; 1.29) 0.260

§, the same patient is taken into account multiple times. CH, chemotherapy (cyclophosphamide/low-dose melphalan/bendamustine/doxorubicine/liposomal doxorubicine/melflufen); CR, complete response; FISH, fluorescence in situ hybridisation; IMID, immunomodulatory agent (thalidomide/lenalidomide/pomalidomide); ISS, international staging system; sCR, stringent complete response; MR, minimal response; PD, progressive disease; PI, proteasome inhibitor (bortezomib/carfilzomib/ixazomib); PR, partial response; SD, stable disease; VGPR, very good partial response; WBLDCT, whole-body low-dose computer tomography.